Abstract

Isha Ajeet Dadhich^*, Neil Biren Panchal, Khushi Ajeet Dadhich and Chhatta Siddhartha Dadhich

DOI : http://dx.doi.org/10.13005/ojc/400415

Alzheimer’s disease (AD) is a significant global health challenge, creating an urgent need for new therapeutic agents. This study explores benzimidazole derivatives as promising candidates for AD treatment. We conducted a comprehensive analysis of these compounds, focusing on their structure-activity relationship (SAR) in combating AD. The detailed SAR analysis identifies the structural features that enhance therapeutic effectiveness, guiding the design of a series of novel benzimidazole-based molecules.
These compounds were thoroughly studied using computational methods, including molecular docking, to predict their binding affinities and interactions with AD-related targets. We also assessed the pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), of the designed compounds to ensure they exhibit favorable drug-like properties and good bioavailability. The molecular docking studies provided valuable insights into how benzimidazole derivatives interact with key enzymes involved in AD, such as acetylcholinesterase and beta-secretase.
Our findings highlight the potential of benzimidazole derivatives as potent anti-Alzheimer agents, offering a promising path for therapeutic development. By integrating SAR analysis, computational modeling, pharmacokinetic profiling, and molecular docking studies, we have established a solid framework for identifying effective compounds for AD treatment. This comprehensive approach not only enhances our understanding of benzimidazole derivatives but also sets the stage for future in vivo studies and clinical trials, ultimately aiming to reduce the global burden of Alzheimer’s disease.

Alzheimer's disease (AD); Benzimidazole derivatives; Molecular docking; Pharmacokinetic profiling (ADME); Structure-activity relationship (SAR)

[ View HTML Full Text]